Evidence map›Paper›PMID 39159002›Full record

ReviewStem cells translational medicine2024

Recent progress in modeling and treating diabetes using stem cell-derived islets.

Marlie M Maestas, Maggie H Bui, Jeffrey R Millman

Abstract readReview
In one paragraph

Review in Stem cells translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. ProtectiveiScience · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marlie M MaestasRoy and Diana Vagelos Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, MO 63110, United States.
Maggie H BuiRoy and Diana Vagelos Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, MO 63110, United States.
Jeffrey R MillmanRoy and Diana Vagelos Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, MO 63110, United States.ORCID 0000-0003-0426-3492

Funding

TRAINING PROGRAM IN CELLULAR AND MOLECULAR BIOLOGYT32GM007067 · NIGMS · WASHINGTON UNIVERSITY · PI TRUE-KROB, HEATHER L · 1985 to 2020
$20.4M
Training Program in Cellular and Molecular BiologyT32GM139774 · NIGMS · WASHINGTON UNIVERSITY · PI HEATHER L TRUE-KROB · 2021 to 2026
$6.7M
Determining the mechanism of IFIH1 disease-associated variants on beta-cell and immune responses in Type 1 diabetesR01DK127497 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI MATHEWS, CLAYTON E, MILLMAN, JEFFREY ROBERT · 2020 to 2023
$4.7M
STUDYING THE ROLE OF THE MICROENVIRONMENT ON DIFFERENTIATION AND MATURATION OF BETA CELLSR01DK114233 · NIDDK · WASHINGTON UNIVERSITY · PI Jeffrey Robert Millman · 2017 to 2026
$3.6M
Uncovering the Interplay Among Pancreatic Tissue Types, Inflammation, and Genotypes in Type 1 DiabetesR01DK138469 · NIDDK · WASHINGTON UNIVERSITY · PI Jeffrey Robert Millman, HUBERT M TSE · 2024 to 2026
$811k
Cellular and Molecular Biology Training T32GM139774NIDDK NIH HHS R01 DK114233NIDDK NIH HHS R01 DK127497NIDDK NIH HHS R01 DK138469NIGMS NIH HHS T32 GM007067NIGMS NIH HHS T32 GM139774NIH HHS R01DK114233, R01DK127497, R01DK138469
6 · The paper itself

Abstract

Stem cell-derived islets (SC-islets) offer the potential to be an unlimited source of cells for disease modeling and the treatment of diabetes. SC-islets can be genetically modified, treated with chemical compounds, or differentiated from patient derived stem cells to model diabetes. These models provide insights into disease pathogenesis and vulnerabilities that may be targeted to provide treatment. SC-islets themselves are also being investigated as a cell therapy for diabetes. However, the transplantation process is imperfect; side effects from immunosuppressant use have reduced SC-islet therapeutic potential. Alternative methods to this include encapsulation, use of immunomodulating molecules, and genetic modification of SC-islets. This review covers recent advances using SC-islets to understand different diabetes pathologies and as a cell therapy.

Indexed as

Islets of LangerhansIslets of Langerhans TransplantationAnimalsCell DifferentiationDiabetes MellitusHumansStem CellsStem Cell Transplantationcellular therapydiabetesdiabetes modelingdifferentiationimmunosuppressionpancreatic differentiationpluripotent stem cellstransplantation

Identifiers

PMID39159002
PMCPMC11465181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.